A 28-year-old Indian woman with a history of classical phenylketonuria (PKU), well-controlled on a phenylalanine-restricted diet since infancy, presents to the antenatal clinic at 8 weeks of gestation. Her recent plasma phenylalanine level is 18 mg/dL (normal <2 mg/dL). Ultrasound shows a structurally normal fetus. Which of the following is the most appropriate next step in management?

Explanation

## Maternal PKU Syndrome and Fetal Management **Key Point:** Maternal PKU syndrome occurs when a woman with PKU (regardless of her own phenotype) becomes pregnant. Elevated maternal phenylalanine is teratogenic to the fetus, even if the fetus has normal phenylalanine hydroxylase activity. ### Pathophysiology of Maternal PKU Syndrome 1. **Transplacental transfer**: Phenylalanine crosses the placenta via active transport (LAT1 transporter) 2. **Fetal exposure**: Fetal plasma phenylalanine rises to 2–3 times maternal levels due to concentration gradient 3. **Fetal damage mechanisms**: - Inhibition of tyrosine uptake → reduced dopamine, norepinephrine, and melanin synthesis - Direct neurotoxicity of elevated phenylalanine and phenylpyruvate - Impaired myelination and synaptogenesis - Vascular endothelial damage ### Teratogenic Effects of Maternal PKU (Maternal PKU Syndrome) | Manifestation | Timing | Mechanism | |---|---|---| | **Microcephaly** | Early pregnancy (1st trimester) | Impaired neurogenesis | | **Congenital heart defects** (PDA, ASD, VSD) | Early organogenesis | Endothelial/myocardial damage | | **Intellectual disability** | Throughout pregnancy | Neurotoxicity, impaired myelination | | **Growth restriction** | 2nd/3rd trimester | Nutritional/metabolic effects | | **Hypopigmentation** | Fetal development | Melanin synthesis inhibition | | **Behavioural problems** | Postnatal | Dopamine/serotonin depletion | **High-Yield:** Risk of fetal abnormality is **directly proportional to maternal plasma phenylalanine level**: - Maternal Phe <6 mg/dL → minimal risk (<5% abnormality rate) - Maternal Phe 6–10 mg/dL → moderate risk (10–25% abnormality rate) - Maternal Phe >10 mg/dL → high risk (>50% abnormality rate) ### Management Strategy for Pregnant Women with PKU ```mermaid flowchart TD A[Woman with PKU planning pregnancy]:::outcome --> B{Preconception counselling done?}:::decision B -->|No| C[Counsel on maternal PKU syndrome risk]:::action B -->|Yes| D[Achieve plasma Phe <6 mg/dL before conception]:::action D --> E[Confirm pregnancy]:::outcome E --> F{Current plasma Phe level?}:::decision F -->|<6 mg/dL| G[Continue strict diet, monitor Phe every 1-2 weeks]:::action F -->|6-10 mg/dL| H[Intensify diet, increase medical foods, reduce protein]:::action F -->|>10 mg/dL| I[Urgent dietary intensification, consider specialist referral]:::urgent G --> J[Target: maintain Phe <6 mg/dL throughout pregnancy]:::action H --> J I --> J J --> K[Fetal ultrasound at 18-20 weeks]:::action K --> L[Postnatal screening of infant]:::action ``` ### Current Management at 8 Weeks Gestation **Current plasma phenylalanine = 18 mg/dL** → HIGH RISK for fetal abnormalities **Immediate actions**: 1. **Intensify phenylalanine-restricted diet**: - Reduce natural protein intake further - Increase medical foods (phenylalanine-free amino acid supplements) - Target: achieve plasma Phe <6 mg/dL within 2–4 weeks 2. **Increase monitoring frequency**: Plasma Phe every 1–2 weeks (vs. monthly baseline) 3. **Nutritional counselling**: Ensure adequate calories, tyrosine, iron, folate, calcium 4. **Fetal ultrasound**: Baseline at 18–20 weeks to detect structural abnormalities (cardiac, CNS) 5. **Postnatal planning**: Infant screening and early dietary management if fetus is heterozygous/homozygous for PAH mutations **Clinical Pearl:** Even though the fetus in this case has a 50% chance of being a carrier (heterozygous) or 25% chance of being homozygous for PAH mutations (depending on partner's carrier status), fetal damage is caused by **maternal hyperphenylalanemia**, not fetal genotype. Strict maternal dietary control is the only proven intervention to prevent fetal damage. **Warning:** ~~Fetal damage only occurs if maternal PKU is undiagnosed~~ — this is FALSE. Fetal damage occurs whenever maternal Phe is elevated, regardless of maternal phenotype or whether she is on treatment. The key is achieving target Phe levels during pregnancy.